Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003431 · ClinicalTrials.gov registry record · Phase 1
Flt3L in Treating Patients With Metastatic Colorectal Cancer
A Phase 1 study, sponsored by Duke University.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00003431 is a Phase 1 study that has completed, run by Duke University.
The verdict
NCT00003431, a Phase 1 study, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Flt3L may stimulate a person's immune system and help kill tumor cells. PURPOSE: Phase I trial to study the effectiveness of flt3L given to patients before undergoing surgery to remove metastases from colorectal cancer.
Interventions
- BIOLOGICAL recombinant flt3 ligand
Trial Details
| Field | Value |
|---|---|
| Start Date | 1998-06 |
| Est. Completion | 2001-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003431
The ClinicalTrials.gov registry entry for NCT00003431 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which recombinant flt3 ligand is the first listed.
NCT00003431 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003431 about?
NCT00003431 is a clinical study titled "Flt3L in Treating Patients With Metastatic Colorectal Cancer". RATIONALE: Flt3L may stimulate a person's immune system and help kill tumor cells. PURPOSE: Phase I trial to study the effectiveness of flt3L given to patients before undergoing surgery to remove metastases from colorectal cancer.
What is the current status of trial NCT00003431?
This trial is currently completed. It is a Phase 1 study. The study started on 1998-06. Estimated completion is 2001-05.
What interventions are being tested in trial NCT00003431?
The interventions under investigation include: recombinant flt3 ligand (BIOLOGICAL).
Who is sponsoring clinical trial NCT00003431?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.